Home
Transdermal and Microneedle Drug Delivery
10 November - 11 November 2025
Transdermal and Microneedle Drug Delivery

Join a High-Impact 2-Day Programme


Engage with leading drug development and delivery leaders in a dynamic, expert-led environment. This conference brings together forward-thinking innovators to explore cutting-edge case studies, breakthrough vaccine and therapeutic applications, and the evolving capabilities of transdermal and microneedle technologies.


Transdermal and microneedle patches are hold opportunity to ‘go beyond the needle’ and revolutionise pharmaceutical development, offering enhanced accessibility, and long-term delivery solutions. With applications ranging from improved vaccine distribution to advanced diagnostics, these technologies are able to reshape healthcare by increasing efficacy and expanding global access to life-changing treatments.

Key Topics & Discussions:

  • Breakthroughs in Clinical Data & Vaccine Delivery – Examining real-world success stories and research-backed evidence.
  • Innovative Capabilities & Applications – Exploring how transdermal and microneedle patches are unlocking new therapeutic possibilities.
  • Manufacturing Challenges & Progress – Addressing scalability, regulatory compliance, and formulation advancements.
  • Regulatory Insights & Expert Q&A – Engaging with key regulators and industry leaders to navigate development, approval pathways and market adoption.

FEATURED SPEAKERS

Ajoy Chakrabarti

Ajoy Chakrabarti

Portfolio & Platform Lead, Polio, Bill & Melinda Gates Foundation (Subject to Final Confirmation)
Amir Reichman

Amir Reichman

CEO, Scinai Immunotherapeutics Ltd.
Arabe Ahmed

Arabe Ahmed

Medicinal Technical Specialist, BSI
Brian Pfister

Brian Pfister

Vice President, Gylden Pharma
Conor O Mahony

Conor O Mahony

Principal Researcher, Tyndall National Institute
James Birchall

James Birchall

Deputy Head, School of Pharmacy and Pharmaceutical Sciences, College of Biomedical and Life Sciences, Cardiff University
John Burt

John Burt

CEO, Medherant
Mateusz Hasso-Agopsowicz

Mateusz Hasso-Agopsowicz

Technical Officer, World Health Organization
Muhammet Avcil

Muhammet Avcil

Managing Director, Imperial BioScience
Renske Hesselink

Renske Hesselink

Director MSC Innovations, Coalition for Epidemic Preparedness Innovations (CEPI)
Sanjiv Sharma

Sanjiv Sharma

Senior Lecturer in Infectious Diseases and Antimicrobial Resistance, University of Liverpool
Steve Damon

Steve Damon

CEO, Micron Biomedical
Waleed Faisal

Waleed Faisal

CEO, ArrayPatch Ltd

Ajoy Chakrabarti

Portfolio & Platform Lead, Polio, Bill & Melinda Gates Foundation (Subject to Final Confirmation)
Ajoy Chakrabarti

Amir Reichman

CEO, Scinai Immunotherapeutics Ltd.
Amir Reichman

Mr. Amir Reichman was appointed CEO of Scinai in 2021. He previously led Global Vaccines Engineering Core Technologies at GSK in Belgium and held senior roles in GSK’s global supply chain after its acquisition of Novartis Vaccines, where he served in operational leadership roles in the U.S.
Mr. Reichman’s academic work at Ben-Gurion University contributed to founding NeuroDerm, later acquired for $1.1B. He was its first employee and served as a Senior Scientist. He holds an M.Sc. in Biotechnology Engineering from Ben-Gurion University and an MBA from the Wharton School, University of Pennsylvania.
 

Arabe Ahmed

Medicinal Technical Specialist, BSI
Arabe Ahmed

Arabe Ahmed is a Medicinal Expert in drug–device combination products at BSI, where his role is to provide specialist pharmaceutical affairs, regulatory and strategic support to medical devices and pharmaceutical companies. Prior to joining BSI, Arabe worked for more than 10 years for GSK and Novartis in the UK, and Germany respectively in various pharmaceutical development roles. He holds a doctorate degree in drug delivery research from Julius Maximilian University of Würzburg, Germany, and masters degree in Pharmaceutical Technology form King's College London. In addition, Arabe is a UK registered pharmacist and member of the Royal Pharmaceutical Society of Great Britain.

Brian Pfister

Vice President, Gylden Pharma
Brian Pfister

Dr. Brian Pfister is a Vice President at Gylden USA Corp. where he leads US operations. Gylden USA is a wholly owned subsidiary of UK based Gylden Pharma Limited, a clinical-stage, privately held biotechnology company pioneering the development of 100% synthetic CD8+ T cell-priming immune set-point therapeutic candidates that harness and direct the body’s natural T cell immune response. Brian received his Ph.D. in biochemistry from Rush University and M.B.A. from the University of Notre Dame.

Conor O Mahony

Principal Researcher, Tyndall National Institute
Conor O Mahony

Dr. Conor O’Mahony is a Principal Researcher with the Tyndall National Institute, and an Adjunct Professor at Chongqing Technology and Business University, China. He is currently leading a team focussed on the development of Micro Transdermal Interface Platforms (MicroTIPs) – high-value, wearable systems that combine elements of microneedle devices for transdermal delivery and diagnostics, self-awareness and communications capabilities. These ‘smart patches’ interact with the outermost skin layers in a minimally invasive manner, and will blur the lines between implantable medical devices and the current generation of wearable electronics.

James Birchall

Deputy Head, School of Pharmacy and Pharmaceutical Sciences, College of Biomedical and Life Sciences, Cardiff University
James Birchall

James Birchall is Professor of Pharmaceutical Sciences and Deputy Head of the School of Pharmacy and Pharmaceutical Sciences, Cardiff University. Professor Birchall graduated from Bath University in 1993 and completed his PhD researching drug and DNA delivery systems in 1998 (Cardiff University). Current research includes pulmonary drug delivery and microneedle delivery of molecules, macromolecules, vaccines, auto-antigens and cells into skin for therapeutic, immunisation or immunotherapy applications.

Professor Birchall has acted as Associate Editor of Critical Reviews in Therapeutic Drug Carrier Systems, a member of the Editorial Board of Expert Review of Medical Devices, a temporary advisor to the WHO and an expert advisor to the British Pharmacopoeia and conducted research funded by the EU, DFID, Bill and Melinda Gates Foundation, NIH, Wellcome Trust, EPSRC, MRC, Welsh Government, Royal Society, Innovate UK and various charities and pharmaceutical companies.
 

John Burt

CEO, Medherant
John Burt

Appointed as CEO of Medherant in 2019 to lead the company in developing novel transdermal drug delivery patches, John Burt was CEO of Abzena plc, a contract research, development and manufacturing organization for biopharmaceuticals, where he led multiple financing rounds, including an AIM IPO in 2014, and grew the business by acquisitions in the UK and US through to the group’s acquisition by private equity firm, Welsh Carson Anderson & Stowe in 2018. He was previously co-founder and CEO of Thiakis, a metabolic disease therapeutic development company that he founded with Professor Steve Bloom out of Imperial College London and subsequently sold to Wyeth in 2008. His early career included finance, business and corporate development roles with Coopers & Lybrand (PwC), Vanguard Medica, Glaxo Wellcome / GlaxoSmithKline and Imperial Innovations. John gained his doctorate in Plant Sciences from University of Oxford following his undergraduate degree in Natural Sciences (Biochemistry) from University of Cambridge.

Mateusz Hasso-Agopsowicz

Technical Officer, World Health Organization
Mateusz Hasso-Agopsowicz

Muhammet Avcil

Managing Director, Imperial BioScience
Muhammet Avcil

Dr Muhammet Avcil gained his honours degree in Chemistry and an MSc in Molecular Synthesis (Organic Syntheses) from the University of Sussex. After his MSc, He worked as a Research Assistant at the University of Sussex. He conducted his PhD research at the University of Sussex and Imperial College London. He has over 19 years of experience in biotechnology, drug discovery and development, working at universities and senior management positions in various institutions. He is a key figure in the management and strategic development of Imperial Bioscience and continues to get involved in the research and development of the company.
 

Renske Hesselink

Director MSC Innovations, Coalition for Epidemic Preparedness Innovations (CEPI)
Renske Hesselink

Sanjiv Sharma

Senior Lecturer in Infectious Diseases and Antimicrobial Resistance, University of Liverpool
Sanjiv Sharma

Dr Sanjiv Sharma received his PhD on the development of analytical methods for determination of certain pharmaceuticals and their metabolites using miniaturised separation system in 2001. On completion of his fellowship he joined the Institute of Biomedical Engineering, Imperial College London to work with Professor Tony Cass in the area of Bionanotechnology and Biosensors. Here he developed minimally invasive microneedles, from photolithographic fabrication to high throughput fabrication, taking these microneedles from the lab to the clinic . Sanjiv was involved in a NIHR (i4i) funded research project involving clinical studies in healthy volunteers and participants with T1D with renowned Endocrinologist Clinicians; Professor Desmond Johnston and Professor Nick Oliver. He has published over 50 research articles and has patents filed in Germany, UK and the United States.
Sanjiv is currently a Senior Lecturer in Medical Engineering in the College of Engineering at Swansea University. At Swansea, he is working on therapeutic drug delivery and diagnostic (theranostic) applications of polymeric microneedles.
 

Senior Representative

, Vaxxas
Senior Representative

Steve Damon

CEO, Micron Biomedical
Steve Damon

Mr. Damon is an industry veteran who has over 30 years of experience with various business roles in the medical device and pharmaceutical industries. He served as the CEO and President of 4P Therapeutics, a company he founded in 2011 and sold to Nutriband Inc. in 2018. He served as Chairman and President of Absorbable Polymers International, a company he founded in 2003 as a wholly owned subsidiary of DURECT corporation. Steve has held Executive positions in Mergers & Acquisitions, Business Development and Commercial Development for several companies including Femasys, Altea Therapeutics, DURECT and Kimberly-Clark Health Care.
In addition to his role with Micron, Steve serves on the Board of Directors for Temple Therapeutics. He is a long-time member of Georgia Bio and serves on its Board of Directors.
 

Waleed Faisal

CEO, ArrayPatch Ltd
Waleed Faisal

Dr Waleed Faisal is co-founder and Chief Executive Officer of ArrayPatch Ltd. Dr. Faisal led several Enterprise Ireland projects with a budget exceeding €1.3M, leading to the formation of ArrayPatch Ltd. He is a named inventor on the DerMapTM technology patent. Prior to this, he was Quality Assurance scientist at Xeolas Pharmaceuticals Ltd. Dr Faisal is a formulation scientist by training having earned a PhD Pharmaceuticals at UCC, and was recognized among Ireland’s top 100 healthcare achievers in 2022. To date, he has led the technology to multiple awards including Irish Pharma Awards 2022, Ideate Ireland Award 2023 and SSPC Commercial Activity of the Year 2022.

Conference agenda

clock

8:00

Registration & Coffee

clock

9:00

Chair's Opening Remarks

Sanjiv Sharma, Senior Lecturer in Infectious Diseases and Antimicrobial Resistance, University of Liverpool

clock

9:10

Microneedles for Long-Acting Drug Therapy

James Birchall, Deputy Head, School of Pharmacy and Pharmaceutical Sciences, College of Biomedical and Life Sciences, Cardiff University

  • Developing microneedles for optimised drug release control for the delivery of long acting therapies
  • Utilising microneedle technology as a minimally invasive and user-friendly delivery method, and to enhance adherence to long-acting treatments
  • Opportunities in expanding therapeutic applications, from vaccines to chronic disease management
  • Future directions: discussing advances in materials, formulation, preclinical models and regulatory pathways to drive widespread adoption
  • clock

    9:50

    Navigating Regulatory Challenges in Transdermal Drug Delivery

    Arabe Ahmed, Medicinal Technical Specialist, BSI

  • Reviewing the impact of MDR and Article 117 and understanding how the requirements affect transdermal drug delivery systems
  • Delving into manufacturer responsibilities and ensuring compliance with quality, safety, and efficacy standards for transdermal products
  • Efficiently handling changes in drug formulations and patch technology
  • Strategies for demonstrating regulatory compliance and clinical effectiveness
  • clock

    10:30

    Morning Coffee

    clock

    11:00

    Delivery of cancer immunotherapeutics using microneedle technologies to achieve contextual T cell Priming

    Brian Pfister, Vice President, Gylden Pharma

  • Cancer immunotherapeutic strategies
  • Nanoparticle and microneedle technologies for delivery of antigens to skin resident dendritic cell populations
  • Early clinical data treating pancreatic cancer
  • clock

    11:40

    Session Reserved for Sponsor

    clock

    12:10

    Beyond Delivery: Harnessing Transdermal Diagnostics for Precision Medicine

    Sanjiv Sharma, Senior Lecturer in Infectious Diseases and Antimicrobial Resistance, University of Liverpool

  • Exploring how transdermal diagnostic technologies compliment transdermal drug delivery for real-time monitoring
  • Innovations in microneedle-based and wearable biosensors for continuous biomarker tracking
  • How transdermal diagnostics can enable adaptive drug dosing and improve therapeutic outcomes
  • Addressing scalability, regulatory hurdles, and commercialization pathways for transdermal diagnostics
  • clock

    12:50

    Networking Lunch

    clock

    14:00

    Intradermal Delivery of Anti-IL-17A/F VHH Antibody for Plaque Psoriasis Treatment

    Amir Reichman, CEO, Scinai Immunotherapeutics Ltd.

  • Exploring targeted intradermal administration and approaches for enhancing drug delivery efficiency for localised psoriasis treatment
  • Reviewing advantages of VHH Antibody fragments including improved stability, penetration, and therapeutic potential
  • Clinical and translational considerations, highlight strategies for optimising formulation and delivery for patient outcomes
  • Outlook on future applications and development - expanding microneedle and transdermal technology for dermatological treatments
  • clock

    14:40

    Session Reserved for Sponsor

    clock

    15:10

    Development of a testosterone patch for women using novel S-PURE adhesive technology

    John Burt, CEO, Medherant

  • S-PURE cross-linked adhesive has superior characteristics for drug delivery patches
  • Clinical need for testosterone patch for post-menopausal women
  • Formulation development for optimised transdermal API delivery
  • Phase 1 pharmacokinetics of testosterone patch
  • clock

    15:50

    Afternoon Tea

    clock

    16:20

    Revolutionising Treatment Through Advanced Microneedle Systems

    Conor O Mahony, Principal Researcher, Tyndall National Institute

  • Enhancing patient comfort with minimally invasive and self-administered treatments
  • Programmable Microfluidics: On-demand, adaptive drug release with precision dosing control for personalised therapy
  • Integrating biosensors for real-time drug monitoring, feedback systems, and remote diagnostics
  • Implementing sustainable design with biodegradable, recyclable microneedle platforms
  • clock

    17:00

    Fireside Chat: The Future of Transdermal & Microneedle Therapeutics

  • Key takeaways on therapeutic opportunities and real-world applications, highlighting how transdermal and microneedle technologies are shaping the future of drug delivery, patient accessibility, and treatment effectiveness
  • Navigating Development & Commercialisation Challenges – Addressing regulatory hurdles, manufacturing scalability, and market adoption and potential strategic approaches for overcoming these obstacles
  • Looking ahead to emerging technologies, investment priorities, and industry growth – Exploring cutting-edge innovations, the evolving role of microneedle and transdermal delivery systems, and the key investment trends that will drive future advancements in biopharma and healthcare applications
  • Sanjiv Sharma, Senior Lecturer in Infectious Diseases and Antimicrobial Resistance, University of Liverpool

    James Birchall, Deputy Head, School of Pharmacy and Pharmaceutical Sciences, College of Biomedical and Life Sciences, Cardiff University

    John Burt, CEO, Medherant

    Amir Reichman, CEO, Scinai Immunotherapeutics Ltd.

    clock

    17:40

    Chair’s Closing Remarks and Close of Day One

    clock

    8:30

    Registration & Coffee

    clock

    9:00

    Chair's Opening Remarks

    Sanjiv Sharma, Senior Lecturer in Infectious Diseases and Antimicrobial Resistance, University of Liverpool

    clock

    9:10

    Advancing Vaccine Delivery: Microarray Patch Technology in Support of CEPI’s 100-Days Mission

  • CEPI aims to prepare the world for epidemics and pandemics, by accelerating vaccine development and enabling equitable access
  • Vaccine patches play an important role in this mission, because of their distribution and delivery advantages
  • Microarray patch platform technology development is essential for pandemic preparedness, to be able to use these patches in a rapid response situation
  • clock

    9:50

    Microneedle Patch Technology: From Pre-clinical Success to First-in-Human

    Muhammet Avcil, Managing Director, Imperial BioScience

  • Translating pre-clinical insights into early human studies
  • Meeting key safety & regulatory milestones
  • Pathways for scale-up and commercial adoption
  • clock

    10:30

    Morning Coffee

    clock

    11:00

    Priority implementation research to inform integration of MAPs into immunization programmes

    Mateusz Hasso-Agopsowicz

    Mateusz Hasso-Agopsowicz, Technical Officer, World Health Organization

  • Key areas of study needed to facilitate the seamless adoption of microneedle array patches (MAPs) in immunization programmes
  • Addressing regulatory, logistical, and operational barriers while leveraging MAP advantages for broader vaccine coverage
  • Leveraging real-world data and pilot studies to inform policy decisions and optimize MAP distribution
  • Exploring global partnerships, funding opportunities, and next steps to accelerate MAP adoption
  • clock

    11:40

    Session Reserved for Sponsor

    clock

    12:10

    Microneedles in drug products: Payer value drivers

    Waleed Faisal, CEO, ArrayPatch Ltd

  • Unmet need
  • Payer value drivers
  • Clinical evidence: Case study DerMap in onychomycosis
  • Strategic recommendations
  • clock

    12:50

    Networking Lunch

    clock

    14:00

    Strategically Developing Vaccine Delivery Technologies for Global Health

    Steve Damon, CEO, Micron Biomedical

  • Insight into Micron’s microarray technology
  • Reviewing key packaging and technology considerations for finding successful alternatives to administer vaccines than traditional routes
  • Discussing the key needs from partnerships in the space for effective technology development and outcomes
  • clock

    14:40

    Session Reserved for Sponsor

    clock

    15:10

    Afternoon Tea

    clock

    15:40

    Transforming the vaccine landscape with the development of needle-free vaccine patches

    Senior Representative

    Senior Representative , , Vaxxas

  • Exploring HD-MAP technology for vaccine administration
  • Learnings from recent usability and accessibility studies
  • Advantages of needle-free vaccine delivery
  • clock

    16:20

    Advancing the potential of microarray patches (MAPs) for effective vaccine and therapeutic delivery

  • Reviewing the current landscape of MAP technology and latest developments in the field
  • Outlining challenges in MAP development including cost of goods, cold chain and regulatory uncertainties, and potential approaches to overcome these
  • Exploring the use of AI in programs and the potential benefits
  • Examples of current collaboration and partnerships, and how these can be utilised to drive future success in the development, deployment and use of MAPs
  • Ajoy Chakrabarti

    Ajoy Chakrabarti , Portfolio & Platform Lead, Polio, Bill & Melinda Gates Foundation (Subject to Final Confirmation)

    Steve Damon, CEO, Micron Biomedical

    Senior Representative

    Senior Representative , , Vaxxas

    clock

    17:00

    Chair’s Closing Remarks and Close of Day Two


    Portfolio & Platform Lead, Polio
    Bill & Melinda Gates Foundation (Subject to Final Confirmation)
    CEO
    Scinai Immunotherapeutics Ltd.
    Medicinal Technical Specialist
    BSI
    Vice President
    Gylden Pharma
    Principal Researcher
    Tyndall National Institute
    Deputy Head, School of Pharmacy and Pharmaceutical Sciences, College of Biomedical and Life Sciences
    Cardiff University
    CEO
    Medherant
    Technical Officer
    World Health Organization
    Managing Director
    Imperial BioScience
    Director MSC Innovations
    Coalition for Epidemic Preparedness Innovations (CEPI)
    Senior Lecturer in Infectious Diseases and Antimicrobial Resistance
    University of Liverpool
    Vaxxas
    CEO
    Micron Biomedical
    CEO
    ArrayPatch Ltd

    Official Media Partner

    VENUE

    Hilton London Kensington

    179-199 Holland Park Avenue, London, United Kingdom

    At the heart of the Holland Park district, our hotel is 10 minutes from Westfield London shopping center. We're blocks from Shepherd's Bush Underground station, linking to central London, and Kensington Palace and Gardens are two miles from us. Enjoy 24-hour access to our fitness center.

     
    Join us in WestEleven for hearty buffet breakfast, a great way to start the day! Our Avenue Bar and Lounge serves light bites throughout the day as well as a delicious, seasonal dining menu.”

    A number of our clients have been approached by third party organisations offering to book hotel rooms. We would advise that you do not book through them as they are not representing SMi Group Trading As SAE Media Group. SMi Group Trading As SAE Media Group books all hotel rooms directly. If you are approached by a third-party organisation then please contact us before making any bookings. If you have already booked a hotel room using a third-party organisation, we would highly recommend contacting the hotel you were booked into to ensure a booking has been made for you. We would also advise you to please check the terms and conditions of the booking carefully.
    HOTEL BOOKING FORM

    Media Partners


    Drug Development and Delivery

    Official Media Partner
    http://drug-dev.com/

    Drug Development & Delivery, including its exclusive Specialty Pharma section, is a print publication, conference organizer (Drug Development Networking Summit), and online content provider exclusively committed to advancing the applied science, technology, and related business practices of pharmaceutical and biological drug development, reporting on formulation design, bioavailability and solubility enhancement, drug delivery and platform technologies, life cycle management, compound-enabling strategies, business development, outsourcing services, and partnerships and collaborations. Through insightful scientific, business, news, and technology-related formats, Drug Development & Delivery provides pharmaceutical professionals with practical solutions to the issues, opportunities, and challenges in the ever-evolving drug development communities. We complement your business development initiatives, connecting you with and influencing the audiences that matter most to you: investors, business partners, technology and service seekers, and regulatory agencies.


    The Medicine Maker

    Official Media Partner
    https://themedicinemaker.com/?utm_source=media_partner_24&utm_medium=event&utm_campaign=sae_media_logo

    The Medicine Maker is a print and digital publication as well as a weekly newsletter. At The Medicine Maker, we bring people into the limelight, showcasing the industry’s success stories and examining its biggest points of contention. Engaging content covers the entire spectrum of drug development, keeping all medicine makers up to date with the most pressing topics, trends and technologies driving the pharma industry forward. Register for your FREE print or digital magazine or subscribe to our newsletter here! https://themedicinemaker.com/?utm_source=media_partner_24&utm_medium=event&utm_campaign=sae_media_logo


    pharmaphorum

    Official Media Partner
    http://www.pharmaphorum.com

    pharmaphorum drives innovation within the pharmaceutical industry, by bringing healthcare together through a suite of media services that help produce and disseminate thought leadership, combined with an online platform for communicating messages to a global audience.Visit www.pharmaphorum.com


    Pharma Journalist

    Official Media Partner
    http://www.pharmajournalist.com

    Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry. Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry. Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.


    ONdrugDelivery

    Official Media Partner
    http://ondrugdelivery.com

    ONdrugDelivery provides readers throughout global pharma/biopharma with the latest, most pertinent industry information and intelligence about the drug delivery-related ideas, technologies, services and products the sector is developing. Established in 2004, and trusted throughout the industry for its high quality contributions from leading drug delivery experts, ONdrugDelivery is a must for pharma / biotech industry professionals who need to know what’s going on in drug delivery. Subscribe online today to the print or free digital edition: ondrugdelivery.com/subscribe

    SAVE TO


    Outlook Calendar  OUTLOOK CALENDAR
    Google Calendar  GOOGLE CALENDAR
    ICal Calendar  ICAL CALENDAR
    Yahoo! Calendar  YAHOO! CALENDAR

    Hilton London Kensington

    179-199 Holland Park Avenue
    London W11 4UL
    United Kingdom

    Hilton London Kensington

    At the heart of the Holland Park district, our hotel is 10 minutes from Westfield London shopping center. We're blocks from Shepherd's Bush Underground station, linking to central London, and Kensington Palace and Gardens are two miles from us. Enjoy 24-hour access to our fitness center.

     
    Join us in WestEleven for hearty buffet breakfast, a great way to start the day! Our Avenue Bar and Lounge serves light bites throughout the day as well as a delicious, seasonal dining menu.”
    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download

    Title


    Description

    Download

    Title


    Description


    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@saemediagroup.com

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    Group Booking

    Please complete the below form and a member of SAE Media Group’s booking team will be in contact within 24 hours

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SAE Media Group

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smgconferences.com Email: events@saemediagroup.com
    Registered in England - SMi Group Ltd trading as SAE Media Group




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SAE Media Group.
    Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data.privacy@smgconferences.com.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out

    Fill in your details to download the brochure

    By submitting this form you agree to our privacy policy and consent to receiving communications, you may opt out at any time.

    Join the loitering munitions community

    Keep up to date with industry news, insights, and community updates FREE and direct to your inbox every month!
    You can unsubscribe at any time. For full details see our Privacy Policy